Skip to content

Translational Psychiatry

ISSN 2158-3188

151 papers in the library · 4,545 citations · publishing 2012-2026

Papers

Sort Most recent Most cited

A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans

Translational Psychiatry November 18, 2019 Zhongshan Cheng, Chureerat Phokaew, Yi-Ling Chou et al. 4 citations

Abstract Cannabis, the most widely used illicit drug, can induce hallucinations. Our understanding of the biology of cannabis-induced hallucinations (Ca-HL) is limited. We used the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA) to identify cannabis-induced hallucinations (Ca-HL) among long-term cannabis users (used cannabis ≥1 year and ≥100 times). A genome-wide...

DOI: 10.1038/s41398-019-0639-7 (opens in new tab) Full text (opens in new tab) Cannabis Genome-wide association study Meta-analysis Single-nucleotide polymorphism +3

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites

Translational Psychiatry November 7, 2019 Chun Yang, Jianjun Yang, A. Luo et al. 189 citations

Although the robust antidepressant effects of the N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and cellular mechanisms underlying its antidepressant effects remain unknown. NMDAR inhibition and the subsequent α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) activation are...

Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function.

Translational Psychiatry September 5, 2018 Celia J. A. Morgan, Tom P. Freeman, Chandni Hindocha et al.

The main active ingredient in cannabis, delta-9-tetrahydrocannabinol (THC), can acutely induce psychotic symptoms and impair episodic and working memory. Another major constituent, cannabidiol (CBD), may attenuate these effects. This study aimed to determine the effects of THC and CBD, both alone and in combination on psychotic symptoms and memory function. A randomised, double-blind crossover...

Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain

Translational Psychiatry July 16, 2018 Kai‐Chun Yang, Akihiro Takano, Christer Halldin et al. 17 citations

Abstract The serotonin (5-HT) system plays an important role in the pathophysiology and treatment of several major psychiatric disorders. Currently, no suitable positron emission tomography (PET) imaging paradigm is available to assess 5-HT release in the living human brain. [11C]AZ10419369 binds to 5-HT1Breceptors and is one of the most 5-HT-sensitive radioligands available. This study applied...

NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.

Translational Psychiatry June 15, 2018 Brigitte Vanle, William Olcott, Jaime Jimenez et al.

Among patients with Parkinson's disease (PD), depression is prevalent and disabling, impacting both health outcomes and quality of life. There is a critical need for alternative pharmacological methods to treat PD depression, as mainstream antidepressant drugs are largely ineffective in this population. Currently, there are no recommendations for the optimal treatment of PD neuropsychiatric...

THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders.

Translational Psychiatry April 25, 2018 Boris Guennewig, Maina Bitar, Ifeanyi Obiorah et al.

There is a strong association between cannabis use and schizophrenia but the underlying cellular links are poorly understood. Neurons derived from human-induced pluripotent stem cells (hiPSCs) offer a platform for investigating both baseline and dynamic changes in human neural cells. Here, we exposed neurons derived from hiPSCs to Δ9-tetrahydrocannabinol (THC), and identified diagnosis-specific...

Aberrant salience network functional connectivity in auditory verbal hallucinations: a first episode psychosis sample

Translational Psychiatry March 27, 2018 Pavan Mallikarjun, P. Lalousis, T. Dunne et al.

Auditory verbal hallucinations (AVH) often lead to distress and functional disability, and are frequently associated with psychotic illness. Previously both state and trait magnetic resonance imaging (MRI) studies of AVH have identified activity in brain regions involving auditory processing, language, memory and areas of default mode network (DMN) and salience network (SN). Current evidence is...

Possible role of the gut microbiota–brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model

Translational Psychiatry December 15, 2017 Chun Yang, Youge Qu, Yuko Fujita et al. 231 citations

Accumulating evidence suggests that the gut microbiota-brain axis plays a role in the pathogenesis of depression, thereby contributing to the antidepressant actions of certain compounds. (R)-ketamine has a greater potency and longer-lasting antidepressant effects than (S)-ketamine. Here, we investigated whether the gut microbiota plays a role in the antidepressant effects of these two ketamine...

Ketamine: differential neurophysiological dynamics in functional networks in the rat brain.

Translational Psychiatry September 19, 2017 A Ahnaou, H Huysmans, R Biermans et al.

Recently, the N-methyl-d-aspartate-receptor (NMDAR) antagonist ketamine has emerged as a fast-onset mechanism to achieve antidepressant activity, whereas its psychomimetic, dissociative and amnestic effects have been well documented to pharmacologically model schizophrenia features in rodents. Sleep-wake architecture, neuronal oscillations and network connectivity are key mechanisms supporting...

Plasma REST: a novel candidate biomarker of Alzheimer's disease is modified by psychological intervention in an at-risk population.

Translational Psychiatry June 6, 2017 N J Ashton, A Hye, C A Leckey et al.

The repressor element 1-silencing transcription (REST) factor is a key regulator of the aging brain's stress response. It is reduced in conditions of stress and Alzheimer's disease (AD), which suggests that increasing REST may be neuroprotective. REST can be measured peripherally in blood plasma. Our study aimed to (1) examine plasma REST levels in relation to clinical and biological markers of...

Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects

Translational Psychiatry April 4, 2017 Felix Mueller, Claudia Lenz, Patrick C. Dolder et al. 124 citations

Abstract Lysergic acid diethylamide (LSD) induces profound changes in various mental domains, including perception, self-awareness and emotions. We used functional magnetic resonance imaging (fMRI) to investigate the acute effects of LSD on the neural substrate of emotional processing in humans. Using a double-blind, randomised, cross-over study design, placebo or 100 μg LSD were orally...

Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome

Translational Psychiatry March 21, 2017 Drew D. Kiraly, Sarah R. Horn, Nicholas T. van Dam et al. 182 citations

Abstract A subset of patients with depression have elevated levels of inflammatory cytokines, and some studies demonstrate interaction between inflammatory factors and treatment outcome. However, most studies focus on only a narrow subset of factors in a patient sample. In the current study, we analyzed broad immune profiles in blood from patients with treatment-resistant depression (TRD) at...

Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males

Translational Psychiatry November 29, 2016 Claire Mokrysz, Tom P. Freeman, Saana M. Korkki et al. 111 citations

Preclinical research demonstrates that cannabinoids have differing effects in adolescent and adult animals. Whether these findings translate to humans has not yet been investigated. Here we believe we conducted the first study to compare the acute effects of cannabis in human adolescent (n=20; 16-17 years old) and adult (n=20; 24-28 years old) male cannabis users, in a placebo-controlled,...

Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants

Translational Psychiatry September 20, 2016 Daniel M. Rotroff, Daniel Corum, Alison A. Motsinger‐Reif et al. 99 citations

Ketamine, at sub-anesthetic doses, is reported to rapidly decrease depression symptoms in patients with treatment-resistant major depressive disorder (MDD). Many patients do not respond to currently available antidepressants, (for example, serotonin reuptake inhibitors), making ketamine and its enantiomer, esketamine, potentially attractive options for treatment-resistant MDD. Although...

Meditation and vacation effects have an impact on disease-associated molecular phenotypes.

Translational Psychiatry August 30, 2016 Elissa S Epel, E Puterman, J Lin et al.

Meditation is becoming increasingly practiced, especially for stress-related medical conditions. Meditation may improve cellular health; however, studies have not separated out effects of meditation from vacation-like effects in a residential randomized controlled trial. We recruited healthy women non-meditators to live at a resort for 6 days and randomized to either meditation retreat or...

Ibogaine and addiction in the animal model, a systematic review and meta-analysis.

Translational Psychiatry May 31, 2016 Maarten Belgers, M Leenaars, Judith R. Homberg et al. 64 citations

Ibogaine is a naturally occurring substance which has been increasingly used in the lay-scene to reduce craving and relapse in patients with substance use disorders (SUDs). Although human clinical trials on the safety and efficacy of ibogaine are lacking, animal studies do support the efficacy of ibogaine. In this systematic review and meta-analysis (MA), we summarise these animal findings,...

DOI: 10.1038/tp.2016.71 (opens in new tab) Full text (opens in new tab) Ibogaine Addiction treatment Drug self-administration reduction Curbing addictive behaviors +11

Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model

Translational Psychiatry February 23, 2016 H-L Sun, Z-Q Zhou, G.-F. Zhang et al. 87 citations

Although ketamine shows a rapid and sustained antidepressant effect, the precise mechanisms underlying its effect are unknown. Recent studies indicate a key role of p11 (also known as S100A10) in depression-like behavior in rodents. The present study aimed to investigate the role of p11 in the antidepressant-like action of ketamine in chronic unpredictable mild stress (CUMS) rat model. The...

DOI: 10.1038/tp.2016.21 (opens in new tab) Full text (opens in new tab) Ketamine Behavioural despair test Hippocampus Open field +9

AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers.

Translational Psychiatry February 16, 2016 C J A Morgan, Tom P. Freeman, J Powell et al.

Smoking cannabis daily doubles an individual's risk of developing a psychotic disorder, yet indicators of specific vulnerability have proved largely elusive. Genetic variation is one potential risk modifier. Single-nucleotide polymorphisms in the AKT1 and catechol-O-methyltransferase (COMT) genes have been implicated in the interaction between cannabis, psychosis and cognition, but no studies...

Hippocampal harms, protection and recovery following regular cannabis use.

Translational Psychiatry January 12, 2016 Murat Yücel, Valentina Lorenzetti, Chao Suo et al.

Shifting policies towards legalisation of cannabis for therapeutic and recreational use raise significant ethical issues for health-care providers seeking evidence-based recommendations. We investigated whether heavy cannabis use is associated with persistent harms to the hippocampus, if exposure to cannabidiol offers protection, and whether recovery occurs with abstinence. To do this, we...

3,4-Methylenedioxymethamphetamine facilitates fear extinction learning

Translational Psychiatry September 15, 2015 Matthew B Young, Raül Andero, Kerry J. Ressler et al. 137 citations

Abstract Acutely administered 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) has been proposed to have long-term positive effects on post-traumatic stress disorder (PTSD) symptoms when combined with psychotherapy. No preclinical data support a mechanistic basis for these claims. Given the persistent nature of psychotherapeutic gains facilitated by MDMA, we hypothesized that MDMA improves...

Delayed emergence of behavioral and electrophysiological effects following juvenile ketamine exposure in mice

Translational Psychiatry September 15, 2015 L.R. Nagy, Robert E. Featherstone, Chang-Gyu Hahn et al. 24 citations

Frequent ketamine abuse in adulthood correlates with increased risk of psychosis, as well as cognitive deficits, including disruption of higher-order executive function and memory formation. Although the primary abusers of ketamine are adolescents and young adults, few studies have evaluated its effects on juvenile cognition. Therefore, the current study analyzes the effect of adolescent...

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects

Translational Psychiatry September 1, 2015 Chun Yang, Yukihiko Shirayama, J-C Zhang et al. 600 citations

Although the efficacy of racemate ketamine, a rapid onset and sustained antidepressant, for patients with treatment-resistant depression was a serendipitous finding, clinical use of ketamine is limited, due to psychotomimetic side effects and abuse liability. Behavioral and side-effect evaluation tests were applied to compare the two stereoisomers of ketamine. To elucidate their potential...

DOI: 10.1038/tp.2015.136 (opens in new tab) Full text (opens in new tab) Ketamine Psychotomimetic Antidepressant Nucleus accumbens +8

Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder

Translational Psychiatry February 17, 2015 James W. Murrough, Katherine A. Collins, Jessica Fields et al. 111 citations

The glutamate N-methyl-D-aspartate receptor antagonist ketamine has demonstrated antidepressant effects in individuals with treatment-resistant major depressive disorder (TRD) within 24 h of a single dose. The current study utilized functional magnetic resonance imaging (fMRI) and two separate emotion perception tasks to examine the neural effects of ketamine in patients with TRD. One task used...

Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression

Translational Psychiatry October 14, 2014 Níall Lally, Allison C. Nugent, David A. Luckenbaugh et al. 269 citations

Anhedonia--which is defined as diminished pleasure from, or interest in, previously rewarding activities-is one of two cardinal symptoms of a major depressive episode. However, evidence suggests that standard treatments for depression do little to alleviate the symptoms of anhedonia and may cause reward blunting. Indeed, no therapeutics are currently approved for the treatment of anhedonia....

The effects of ketamine and risperidone on eye movement control in healthy volunteers

Translational Psychiatry December 1, 2013 Anne Schmechtig, J. Lees, A. Perkins et al.

The non-competitive N-methyl-D-aspartate receptor antagonist ketamine leads to transient psychosis-like symptoms and impairments in oculomotor performance in healthy volunteers. This study examined whether the adverse effects of ketamine on oculomotor performance can be reversed by the atypical antipsychotic risperidone. In this randomized double-blind, placebo-controlled study, 72 healthy...